625 related articles for article (PubMed ID: 19668859)
21. Identification and development of 2-methylimidazo[1,2-a]pyridine-3-carboxamides as Mycobacterium tuberculosis pantothenate synthetase inhibitors.
Samala G; Nallangi R; Devi PB; Saxena S; Yadav R; Sridevi JP; Yogeeswari P; Sriram D
Bioorg Med Chem; 2014 Aug; 22(15):4223-32. PubMed ID: 24953948
[TBL] [Abstract][Full Text] [Related]
22. Novel small molecule inhibitors of MDR Mycobacterium tuberculosis by NMR fragment screening of antigen 85C.
Scheich C; Puetter V; Schade M
J Med Chem; 2010 Dec; 53(23):8362-7. PubMed ID: 21073150
[TBL] [Abstract][Full Text] [Related]
23. Comparative protein modeling of methionine S-adenosyltransferase (MAT) enzyme from Mycobacterium tuberculosis: a potential target for antituberculosis drug discovery.
Khedkar SA; Malde AK; Coutinho EC
J Mol Graph Model; 2005 Jan; 23(4):355-66. PubMed ID: 15670956
[TBL] [Abstract][Full Text] [Related]
24. A novel trehalase from Mycobacterium smegmatis - purification, properties, requirements.
Carroll JD; Pastuszak I; Edavana VK; Pan YT; Elbein AD
FEBS J; 2007 Apr; 274(7):1701-14. PubMed ID: 17319935
[TBL] [Abstract][Full Text] [Related]
25. Nanomolar competitive inhibitors of Mycobacterium tuberculosis and Streptomyces coelicolor type II dehydroquinase.
Prazeres VF; Sánchez-Sixto C; Castedo L; Lamb H; Hawkins AR; Riboldi-Tunnicliffe A; Coggins JR; Lapthorn AJ; González-Bello C
ChemMedChem; 2007 Feb; 2(2):194-207. PubMed ID: 17245805
[TBL] [Abstract][Full Text] [Related]
26. Mycolyltransferase from
Goins CM; Dajnowicz S; Smith MD; Parks JM; Ronning DR
J Biol Chem; 2018 Mar; 293(10):3651-3662. PubMed ID: 29352107
[No Abstract] [Full Text] [Related]
27. Synthesis of cinnamoyl ketoamides as hybrid structures of antioxidants and calpain inhibitors.
Yoo YJ; Nam DH; Jung SY; Jang JW; Kim HJ; Jin C; Pae AN; Lee YS
Bioorg Med Chem Lett; 2011 May; 21(10):2850-4. PubMed ID: 21504847
[TBL] [Abstract][Full Text] [Related]
28. Functionalized 3-amino-imidazo[1,2-a]pyridines: a novel class of drug-like Mycobacterium tuberculosis glutamine synthetase inhibitors.
Odell LR; Nilsson MT; Gising J; Lagerlund O; Muthas D; Nordqvist A; Karlén A; Larhed M
Bioorg Med Chem Lett; 2009 Aug; 19(16):4790-3. PubMed ID: 19560924
[TBL] [Abstract][Full Text] [Related]
29. Weak spots inhibition in the
Adewumi AT; Elrashedy A; Soremekun OS; Ajadi MB; Soliman MES
J Biomol Struct Dyn; 2022 Apr; 40(7):2934-2954. PubMed ID: 33155529
[No Abstract] [Full Text] [Related]
30. Antigen 85C-mediated acyl-transfer between synthetic acyl donors and fragments of the arabinan.
Sanki AK; Boucau J; Ronning DR; Sucheck SJ
Glycoconj J; 2009 Jul; 26(5):589-96. PubMed ID: 19052863
[TBL] [Abstract][Full Text] [Related]
31. The Mycobacterium tuberculosis Ag85A is a novel diacylglycerol acyltransferase involved in lipid body formation.
Elamin AA; Stehr M; Spallek R; Rohde M; Singh M
Mol Microbiol; 2011 Sep; 81(6):1577-92. PubMed ID: 21819455
[TBL] [Abstract][Full Text] [Related]
32. Inhibition of mycobacterial growth by plumbagin derivatives.
Mathew R; Kruthiventi AK; Prasad JV; Kumar SP; Srinu G; Chatterji D
Chem Biol Drug Des; 2010 Jul; 76(1):34-42. PubMed ID: 20456370
[TBL] [Abstract][Full Text] [Related]
33. A new family of inhibitors of Mycobacterium tuberculosis thymidine monophosphate kinase.
Gasse C; Huteau V; Douguet D; Munier-Lehmann H; Pochet S
Nucleosides Nucleotides Nucleic Acids; 2007; 26(8-9):1057-61. PubMed ID: 18058536
[No Abstract] [Full Text] [Related]
34. 'Reverse' alpha-ketoamide-based p38 MAP kinase inhibitors.
Montalban AG; Boman E; Chang CD; Ceide SC; Dahl R; Dalesandro D; Delaet NG; Erb E; Gibbs A; Kahl J; Kessler L; Lundström J; Miller S; Nakanishi H; Roberts E; Saiah E; Sullivan R; Wang Z; Larson CJ
Bioorg Med Chem Lett; 2008 Oct; 18(20):5456-9. PubMed ID: 18835164
[TBL] [Abstract][Full Text] [Related]
35. Investigating the structural basis of arylamides to improve potency against M. tuberculosis strain through molecular dynamics simulations.
Punkvang A; Saparpakorn P; Hannongbua S; Wolschann P; Beyer A; Pungpo P
Eur J Med Chem; 2010 Dec; 45(12):5585-93. PubMed ID: 20888672
[TBL] [Abstract][Full Text] [Related]
36. Substitution of the phosphonic acid and hydroxamic acid functionalities of the DXR inhibitor FR900098: an attempt to improve the activity against Mycobacterium tuberculosis.
Andaloussi M; Lindh M; Björkelid C; Suresh S; Wieckowska A; Iyer H; Karlén A; Larhed M
Bioorg Med Chem Lett; 2011 Sep; 21(18):5403-7. PubMed ID: 21824775
[TBL] [Abstract][Full Text] [Related]
37. Synthesis and biological evaluation of new inhibitors of UDP-Galf transferase--a key enzyme in M. tuberculosis cell wall biosynthesis.
Cren S; Gurcha SS; Blake AJ; Besra GS; Thomas NR
Org Biomol Chem; 2004 Sep; 2(17):2418-20. PubMed ID: 15326520
[TBL] [Abstract][Full Text] [Related]
38. Synthesis, biological evaluation, and SAR study of novel pyrazole analogues as inhibitors of Mycobacterium tuberculosis: part 2. Synthesis of rigid pyrazolones.
Castagnolo D; Manetti F; Radi M; Bechi B; Pagano M; De Logu A; Meleddu R; Saddi M; Botta M
Bioorg Med Chem; 2009 Aug; 17(15):5716-21. PubMed ID: 19581099
[TBL] [Abstract][Full Text] [Related]
39. Antimycobacterial activities of novel 2-(sub)-3-fluoro/nitro-5,12-dihydro-5-oxobenzothiazolo[3,2-a]quinoline-6-carboxylic acid.
Dinakaran M; Senthilkumar P; Yogeeswari P; China A; Nagaraja V; Sriram D
Bioorg Med Chem; 2008 Mar; 16(6):3408-18. PubMed ID: 18304818
[TBL] [Abstract][Full Text] [Related]
40. Development of alpha-keto-based inhibitors of cruzain, a cysteine protease implicated in Chagas disease.
Choe Y; Brinen LS; Price MS; Engel JC; Lange M; Grisostomi C; Weston SG; Pallai PV; Cheng H; Hardy LW; Hartsough DS; McMakin M; Tilton RF; Baldino CM; Craik CS
Bioorg Med Chem; 2005 Mar; 13(6):2141-56. PubMed ID: 15727867
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
